To be effective, peptide vaccines must have CD8+ T cell epitopes to activate cytotoxic CTL anti-tumor immunity through the antigen cross-presentation pathway and CD4+ T cell epitopes to activate T helper cells (48). Here, CD8A is linked to neoplasm.